Generation Bio Co Ordinary Shares GBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.36
- Day Range
- $2.31–2.74
- 52-Week Range
- $0.86–4.65
- Bid/Ask
- $2.40 / $2.54
- Market Cap
- $167.52 Mil
- Volume/Avg
- 303,304 / 108,449
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 174
- Website
- https://www.generationbio.com
Comparables
Valuation
|
Metric
|
GBIO
|
SLDB
|
EDIT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.45 | 1.32 | 1.14 |
Price/Sales | 12.62 | — | 3.94 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GBIO
|
SLDB
|
EDIT
|
|---|---|---|---|
Quick Ratio | 7.25 | 12.95 | 3.76 |
Current Ratio | 7.42 | 13.45 | 3.85 |
Interest Coverage | — | — | — |
Quick Ratio
GBIO
SLDB
EDIT
Profitability
|
Metric
|
GBIO
|
SLDB
|
EDIT
|
|---|---|---|---|
Return on Assets (Normalized) | −23.43% | −40.34% | −36.02% |
Return on Equity (Normalized) | −42.83% | −49.74% | −52.20% |
Return on Invested Capital (Normalized) | −33.41% | −47.40% | −52.38% |
Return on Assets
GBIO
SLDB
EDIT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lkgwczysl | Dpws | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Myhznbmd | Ngqpn | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pchjtfgpt | Bqtjb | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nhjbfjpq | Bfwsz | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Gkspdpcf | Wlw | $32.8 Bil | |||
| BioNTech SE ADR
BNTX
| Hsvtbkdly | Mkwbc | $28.3 Bil | |||
| Moderna Inc
MRNA
| Gbmhccw | Crd | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Pxklspxf | Hlqg | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Szfhdhp | Svhnwl | $13.3 Bil | |||
| Incyte Corp
INCY
| Zhjhnkqys | Lhqzsmh | $13.0 Bil |
United States